株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多発性骨髄腫(カーレル病):世界の治験動向

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018

発行 GlobalData 商品コード 225555
出版日 ページ情報 英文 1556 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.58円で換算しております。
Back to Top
多発性骨髄腫(カーレル病):世界の治験動向 Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018
出版日: 2018年02月28日 ページ情報: 英文 1556 Pages
概要

当レポートでは、多発性骨髄腫(カーレル病)に関する臨床研究の最新動向について分析し、疾患の概要を初め、G7諸国・E7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数:多発性骨髄腫(カーレル病)治験件数の腫瘍治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:多発性骨髄腫(カーレル病)治験件数の腫瘍治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別治験件数

有望なスポンサー

治験主要参加企業 - 多発性骨髄腫(カーレル病)治療薬

有望な薬剤

最新治験ニュース:多発性骨髄腫(カーレル病)

治験プロファイルの基本情報

付録

図表

目次
Product Code: GDHC4814CTIDB

GlobalData's clinical trial report, "Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials 30
  • Prominent Drugs 31
  • Latest Clinical Trials News on Multiple Myeloma (Kahler Disease) 32
  • Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology 32
  • Jan 31, 2018: Multiple Myeloma Research Foundation (MMRF) and Karyopharm Collaboration Drives the Advancement of Selinexor, a First-In-Class, Next-Generation Myeloma Therapy 32
  • Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting 33
  • Jan 16, 2018: Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma 33
  • Jan 08, 2018: Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma 34
  • Jan 02, 2018: Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma 34
  • Dec 21, 2017: BioLineRx Announces Initiation of Phase III GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients 35
  • Dec 18, 2017: Poseida Therapeutics Announces First Patient Treated in Phase I Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients With Multiple Myeloma 35
  • Dec 12, 2017: DARZALEX (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible 36
  • Dec 12, 2017: Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies 36
  • Dec 12, 2017: Plitidepsin (PharmaMar) Shows Activity Against the Cells Responsible for the Destruction of Bone in Myeloma Multiple 37
  • Dec 11, 2017: PharmaMar shows new data on plitidepsin for the treatment of multiple myeloma at ASH annual meeting 38
  • Dec 11, 2017: TeneoBio's Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology 38
  • Dec 11, 2017: New Data for DARZALEX (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma 38
  • Dec 11, 2017: Adaptimmune Data Presented at American Society of Hematology (ASH) Annual Meeting for NY ESO SPEAR T-cells in Multiple Myeloma Pilot Study 40
  • Dec 11, 2017: Affimed Presents Preclinical Data on AFM26 at American Society of Hematology (Ash) Annual Meeting and Exposition 2017 40
  • Dec 10, 2017: Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting 41
  • Dec 10, 2017: Karyopharm Presents Data On Selinexor (KPT-330) At The American Society of Hematology 2017 Annual Meeting 42
  • Dec 07, 2017: Glenmark Pharmaceuticals Announces Dosing of First Patient With Investigational Immuno-Oncology Agent GBR 1342 42
  • Dec 07, 2017: Sanofi explores combination treatments for multiple myeloma in new late-stage trials 42
  • Dec 05, 2017: U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma 43
  • Nov 29, 2017: Bristol-Myers Squibb to Present New Data on Multiple Myeloma Drug Elotuzumab at the 59th Annual Meeting & Exposition of the American Society of Hematology 43
  • Nov 29, 2017: Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform 44
  • Clinical Trial Profile Snapshots 46

Appendix 1553

  • Abbreviations 1553
  • Definitions 1553
  • Research Methodology 1554
  • Secondary Research 1554
  • About GlobalData 1555
  • Contact Us 1555
  • Disclaimer 1555
  • Source 1556

List of Tables

List of Tables

  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region, 2018* 8
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018* 16
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018* 19
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase, 2018* 22
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31

List of Figures

List of Figures

  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, G7 Countries (%), 2018* 16
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Multiple Myeloma (Kahler Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Multiple Myeloma (Kahler Disease) to Oncology Clinical Trials, E7 Countries (%), 2018* 19
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
  • Multiple Myeloma (Kahler Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
  • Multiple Myeloma (Kahler Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
  • Multiple Myeloma (Kahler Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 30
  • Multiple Myeloma (Kahler Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 31
  • GlobalData Methodology 1554
Back to Top